Skip to main content
Top
Published in: Journal of Translational Medicine 1/2011

Open Access 01-12-2011 | Research

A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment

Authors: Chi-Jung Huang, Shung-Haur Yang, Shih-Ming Huang, Chih-Ming Lin, Chih-Cheng Chien, Yan-Chu Chen, Chia-Long Lee, Hao-Han Wu, Chun-Chao Chang

Published in: Journal of Translational Medicine | Issue 1/2011

Login to get access

Abstract

Background

Colorectal cancer (CRC) is the predominant gastrointestinal malignancy and the leading cause of cancer death. The identification of genes related to CRC is important for the development of successful therapies and earlier diagnosis.

Methods

Molecular analysis of feces was evaluated as a potential method for CRC detection. Expression of a predicted protein with unknown function, KIAA0247, was found in feces evaluated using specific quantitative real-time polymerase chain reaction. Its cellular function was then analyzed using immunofluorescent staining and the changes in the cell cycle in response to 5-fluorouracil (5-FU) were assessed.

Results

Gastrointestinal tissues and peripheral blood lymphocytes ubiquitously expressed KIAA0247. 56 CRC patients fell into two group categories according to fecal KIAA0247 mRNA expression levels. The group with higher fecal KIAA0247 (n = 22; ≥ 0.4897) had a significantly greater five-year overall survival rate than the group with lower fecal KIAA0247 (n = 30; < 0.4897) (66.0 ± 11.6%; p = 0.035, log-rank test). Fecal expression of KIAA0247 inversely related to CRC tumor size (Kendall's tau-b = -0.202; p = 0.047). Immunofluorescent staining revealed that the cytoplasm of CRC cells evenly expresses KIAA0247 without 5-FU treatment, and KIAA0247 accumulates in the nucleus after 40 μM 5-FU treatment. In HCT116 p53-/- cells, which lack p53 cell cycle control, the proportion of cells in the G2/M phase was larger (13%) in KIAA0247-silent cells than in the respective shLuc control (10%) and KIAA0247-overexpressing cells (7%) after the addition of low dose (40 μM) 5-FU. Expression of three cyclin genes (cyclin A2, cyclin B1, and cyclin B2) also downregulated in the cells overexpressing KIAA0247.

Conclusions

This is the first description of a linkage between KIAA0247 and CRC. The study's data demonstrate overexpression of KIAA0247 associates with 5-FU therapeutic benefits, and also identify the clinical significance of fecal KIAA0247 in CRC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Lieberman D: Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology. 2010, 138: 2115-2126. 10.1053/j.gastro.2010.02.006.CrossRefPubMed Lieberman D: Progress and challenges in colorectal cancer screening and surveillance. Gastroenterology. 2010, 138: 2115-2126. 10.1053/j.gastro.2010.02.006.CrossRefPubMed
2.
go back to reference Kim MS, Lee J, Sidransky D: DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010, 29: 181-206. 10.1007/s10555-010-9207-6.CrossRefPubMed Kim MS, Lee J, Sidransky D: DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010, 29: 181-206. 10.1007/s10555-010-9207-6.CrossRefPubMed
3.
go back to reference Allegra C, Sargent D: Molecular diagnostics: assays, tissues, progress, and pitfalls. J Clin Oncol. 2003, 21: 395-396. 10.1200/JCO.2003.11.073.CrossRefPubMed Allegra C, Sargent D: Molecular diagnostics: assays, tissues, progress, and pitfalls. J Clin Oncol. 2003, 21: 395-396. 10.1200/JCO.2003.11.073.CrossRefPubMed
4.
go back to reference Lagerholm S, Lagerholm S, Dutta S, Nair P: Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol. 2005, 40: 1343-1350. 10.1080/00365520510023549.CrossRefPubMed Lagerholm S, Lagerholm S, Dutta S, Nair P: Non-invasive detection of c-myc p64, c-myc p67 and c-erbb-2 in colorectal cancer. Scand J Gastroenterol. 2005, 40: 1343-1350. 10.1080/00365520510023549.CrossRefPubMed
5.
go back to reference Vogelstein B, Fearon ER, Hamilton SR: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319: 525-532. 10.1056/NEJM198809013190901.CrossRefPubMed Vogelstein B, Fearon ER, Hamilton SR: Genetic alterations during colorectal-tumor development. N Engl J Med. 1988, 319: 525-532. 10.1056/NEJM198809013190901.CrossRefPubMed
6.
go back to reference Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J: Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer. 2006, 6: 265-272. 10.3816/CCC.2006.n.045.CrossRefPubMed Macarulla T, Ramos FJ, Capdevila J, Saura C, Tabernero J: Novel targets for anticancer treatment development in colorectal cancer. Clin Colorectal Cancer. 2006, 6: 265-272. 10.3816/CCC.2006.n.045.CrossRefPubMed
7.
go back to reference Voutsadakis IA: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med. 2007, 11: 252-285. 10.1111/j.1582-4934.2007.00032.x.CrossRefPubMedPubMedCentral Voutsadakis IA: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med. 2007, 11: 252-285. 10.1111/j.1582-4934.2007.00032.x.CrossRefPubMedPubMedCentral
8.
go back to reference DiPaola RS: To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002. Clin Cancer Res. 2002, 8: 3311-3314.PubMed DiPaola RS: To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin. cancer res., 8: 3512-3519, 2002. Clin Cancer Res. 2002, 8: 3311-3314.PubMed
9.
go back to reference Owa T, Yoshino H, Yoshimatsu K, Nagasu T: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem. 2001, 8: 1487-1503.CrossRefPubMed Owa T, Yoshino H, Yoshimatsu K, Nagasu T: Cell cycle regulation in the G1 phase: a promising target for the development of new chemotherapeutic anticancer agents. Curr Med Chem. 2001, 8: 1487-1503.CrossRefPubMed
10.
go back to reference Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999, 59: 4634-4641.PubMed Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res. 1999, 59: 4634-4641.PubMed
11.
go back to reference Hirose Y, Berger MS, Pieper RO: Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001, 61: 5843-5849.PubMed Hirose Y, Berger MS, Pieper RO: Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res. 2001, 61: 5843-5849.PubMed
12.
go back to reference Robles AI, Bemmels NA, Foraker AB, Harris CC: APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001, 61: 6660-6664.PubMed Robles AI, Bemmels NA, Foraker AB, Harris CC: APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res. 2001, 61: 6660-6664.PubMed
13.
go back to reference Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN: The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 2005, 65: 10255-10264. 10.1158/0008-5472.CAN-05-1714.CrossRefPubMedPubMedCentral Staib F, Robles AI, Varticovski L, Wang XW, Zeeberg BR, Sirotin M, Zhurkin VB, Hofseth LJ, Hussain SP, Weinstein JN: The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res. 2005, 65: 10255-10264. 10.1158/0008-5472.CAN-05-1714.CrossRefPubMedPubMedCentral
14.
go back to reference Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology. 2004, 127: 422-427. 10.1053/j.gastro.2004.05.022.CrossRefPubMed Kanaoka S, Yoshida K, Miura N, Sugimura H, Kajimura M: Potential usefulness of detecting cyclooxygenase 2 messenger RNA in feces for colorectal cancer screening. Gastroenterology. 2004, 127: 422-427. 10.1053/j.gastro.2004.05.022.CrossRefPubMed
15.
go back to reference Kawada M, Mizuno M, Nasu J, Uesu T, Okazaki H, Okada H, Shimomura H, Yamamoto K, Tsuji T, Fujita T: Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J Lab Clin Med. 2003, 142: 306-312. 10.1016/S0022-2143(03)00137-9.CrossRefPubMed Kawada M, Mizuno M, Nasu J, Uesu T, Okazaki H, Okada H, Shimomura H, Yamamoto K, Tsuji T, Fujita T: Release of decay-accelerating factor into stools of patients with colorectal cancer by means of cleavage at the site of glycosylphosphatidylinositol anchor. J Lab Clin Med. 2003, 142: 306-312. 10.1016/S0022-2143(03)00137-9.CrossRefPubMed
16.
go back to reference Yang SH, Chien CC, Chen CW, Li SY, Huang CJ: Potential of faecal RNA in diagnosing colorectal cancer. Cancer Lett. 2005, 226: 55-63. 10.1016/j.canlet.2004.11.005.CrossRefPubMed Yang SH, Chien CC, Chen CW, Li SY, Huang CJ: Potential of faecal RNA in diagnosing colorectal cancer. Cancer Lett. 2005, 226: 55-63. 10.1016/j.canlet.2004.11.005.CrossRefPubMed
17.
go back to reference Chang CC, Yang SH, Chien CC, Chen SH, Pan S, Lee CL, Lin CM, Sun HL, Huang CC, Wu YY: Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy. BMC Cancer. 2009, 9: 376-10.1186/1471-2407-9-376.CrossRefPubMedPubMedCentral Chang CC, Yang SH, Chien CC, Chen SH, Pan S, Lee CL, Lin CM, Sun HL, Huang CC, Wu YY: Clinical meaning of age-related expression of fecal cytokeratin 19 in colorectal malignancy. BMC Cancer. 2009, 9: 376-10.1186/1471-2407-9-376.CrossRefPubMedPubMedCentral
18.
go back to reference Huang CJ, Chien CC, Yang SH, Chang CC, Sun HL, Cheng YC, Liu CC, Lin SC, Lin CM: Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med. 2008, 12: 1936-1943.CrossRefPubMedPubMedCentral Huang CJ, Chien CC, Yang SH, Chang CC, Sun HL, Cheng YC, Liu CC, Lin SC, Lin CM: Faecal ribosomal protein L19 is a genetic prognostic factor for survival in colorectal cancer. J Cell Mol Med. 2008, 12: 1936-1943.CrossRefPubMedPubMedCentral
19.
go back to reference Yang RN, Yang SH, Chang CC, Chien CC, Pan S, Huang CJ: Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients. Genet Test Mol Biomarkers. 2010, 14: 703-708. 10.1089/gtmb.2010.0047.CrossRefPubMed Yang RN, Yang SH, Chang CC, Chien CC, Pan S, Huang CJ: Upregulation of fecal cytokeratin 19 is associated with prognosis in older colorectal cancer patients. Genet Test Mol Biomarkers. 2010, 14: 703-708. 10.1089/gtmb.2010.0047.CrossRefPubMed
20.
go back to reference Li J, Tan J, Zhuang L, Banerjee B, Yang X, Chau JF, Lee PL, Hande MP, Li B, Yu Q: Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res. 2007, 67: 11317-11326. 10.1158/0008-5472.CAN-07-1088.CrossRefPubMed Li J, Tan J, Zhuang L, Banerjee B, Yang X, Chau JF, Lee PL, Hande MP, Li B, Yu Q: Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress. Cancer Res. 2007, 67: 11317-11326. 10.1158/0008-5472.CAN-07-1088.CrossRefPubMed
21.
go back to reference Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S: Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene. 1998, 16: 933-943. 10.1038/sj.onc.1201602.CrossRefPubMed Miyake H, Hanada N, Nakamura H, Kagawa S, Fujiwara T, Hara I, Eto H, Gohji K, Arakawa S, Kamidono S: Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene. 1998, 16: 933-943. 10.1038/sj.onc.1201602.CrossRefPubMed
22.
go back to reference Cubas R, Zhang S, Li M, Chen C, Yao Q: Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010, 9: 253-10.1186/1476-4598-9-253.CrossRefPubMedPubMedCentral Cubas R, Zhang S, Li M, Chen C, Yao Q: Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010, 9: 253-10.1186/1476-4598-9-253.CrossRefPubMedPubMedCentral
23.
go back to reference Chang CC, Chien CC, Yang SH, Chen SH, Huang CJ: Identification and Clinical Correlation of Decreased Expression of Cytoplasmic Dynein Heavy Chain 1 in Patients with Colorectal Cancer. Clin Mol Medicine. 2008, 1: 6-10. Chang CC, Chien CC, Yang SH, Chen SH, Huang CJ: Identification and Clinical Correlation of Decreased Expression of Cytoplasmic Dynein Heavy Chain 1 in Patients with Colorectal Cancer. Clin Mol Medicine. 2008, 1: 6-10.
24.
go back to reference Fingerle-Rowson G, Petrenko O: MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div. 2007, 2: 22-10.1186/1747-1028-2-22.CrossRefPubMedPubMedCentral Fingerle-Rowson G, Petrenko O: MIF coordinates the cell cycle with DNA damage checkpoints. Lessons from knockout mouse models. Cell Div. 2007, 2: 22-10.1186/1747-1028-2-22.CrossRefPubMedPubMedCentral
25.
go back to reference Yeh YH, Huang YF, Lin TY, Shieh SY: The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1. Oncogene. 2009, 28: 1366-1378. 10.1038/onc.2008.477.CrossRefPubMed Yeh YH, Huang YF, Lin TY, Shieh SY: The cell cycle checkpoint kinase CHK2 mediates DNA damage-induced stabilization of TTK/hMps1. Oncogene. 2009, 28: 1366-1378. 10.1038/onc.2008.477.CrossRefPubMed
26.
go back to reference Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene. 2001, 20: 1803-1815. 10.1038/sj.onc.1204252.CrossRefPubMed Taylor WR, Stark GR: Regulation of the G2/M transition by p53. Oncogene. 2001, 20: 1803-1815. 10.1038/sj.onc.1204252.CrossRefPubMed
27.
go back to reference Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 1995, 92: 8493-8497. 10.1073/pnas.92.18.8493.CrossRefPubMedPubMedCentral Agarwal ML, Agarwal A, Taylor WR, Stark GR: p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA. 1995, 92: 8493-8497. 10.1073/pnas.92.18.8493.CrossRefPubMedPubMedCentral
28.
go back to reference Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997, 1: 3-11. 10.1016/S1097-2765(00)80002-7.CrossRefPubMed Hermeking H, Lengauer C, Polyak K, He TC, Zhang L, Thiagalingam S, Kinzler KW, Vogelstein B: 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell. 1997, 1: 3-11. 10.1016/S1097-2765(00)80002-7.CrossRefPubMed
29.
go back to reference Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S, Zeillinger R: Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol. 2003, 22: 51-57.PubMed Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S, Zeillinger R: Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol. 2003, 22: 51-57.PubMed
30.
go back to reference Bache M, Dunst J, Wurl P, Frode D, Meye A, Schmidt H, Rath FW, Taubert H: G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines. Anticancer Res. 1999, 19: 1827-1832.PubMed Bache M, Dunst J, Wurl P, Frode D, Meye A, Schmidt H, Rath FW, Taubert H: G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines. Anticancer Res. 1999, 19: 1827-1832.PubMed
31.
32.
go back to reference Gangadhar T, Schilsky RL: Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010, 7: 318-325. 10.1038/nrclinonc.2010.62.CrossRefPubMed Gangadhar T, Schilsky RL: Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010, 7: 318-325. 10.1038/nrclinonc.2010.62.CrossRefPubMed
33.
go back to reference Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR: Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer. 2010, 9: 98-10.1186/1476-4598-9-98.CrossRefPubMedPubMedCentral Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR: Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Mol Cancer. 2010, 9: 98-10.1186/1476-4598-9-98.CrossRefPubMedPubMedCentral
34.
go back to reference Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010, 10: 370-10.1186/1471-2407-10-370.CrossRefPubMedPubMedCentral Sasaki K, Tsuno NH, Sunami E, Tsurita G, Kawai K, Okaji Y, Nishikawa T, Shuno Y, Hongo K, Hiyoshi M: Chloroquine potentiates the anti-cancer effect of 5-fluorouracil on colon cancer cells. BMC Cancer. 2010, 10: 370-10.1186/1471-2407-10-370.CrossRefPubMedPubMedCentral
35.
go back to reference Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet. 2010, 375: 1030-1047. 10.1016/S0140-6736(10)60353-4.CrossRefPubMed Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B, Starling N: Colorectal cancer. Lancet. 2010, 375: 1030-1047. 10.1016/S0140-6736(10)60353-4.CrossRefPubMed
36.
go back to reference Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo M, Murakami T, Gondou T, Minami Y, Takemoto Y: DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther. 2010, 9: 246-252. 10.1158/1535-7163.MCT-09-0495.CrossRefPubMedPubMedCentral Oka K, Tanaka T, Enoki T, Yoshimura K, Ohshima M, Kubo M, Murakami T, Gondou T, Minami Y, Takemoto Y: DNA damage signaling is activated during cancer progression in human colorectal carcinoma. Cancer Biol Ther. 2010, 9: 246-252. 10.1158/1535-7163.MCT-09-0495.CrossRefPubMedPubMedCentral
37.
go back to reference Wei EK, Wolin KY, Colditz GA: Time course of risk factors in cancer etiology and progression. J Clin Oncol. 2010, 28: 4052-4057. 10.1200/JCO.2009.26.9324.CrossRefPubMed Wei EK, Wolin KY, Colditz GA: Time course of risk factors in cancer etiology and progression. J Clin Oncol. 2010, 28: 4052-4057. 10.1200/JCO.2009.26.9324.CrossRefPubMed
38.
go back to reference Chien CC, Chang CC, Yang SH, Chen SH, Huang CJ: A homologue of the Drosophila headcase protein, HECA, is a novel tumor marker for early-stage colorectal cancer. Oncol Rep. 2006, 15: 919-926.PubMed Chien CC, Chang CC, Yang SH, Chen SH, Huang CJ: A homologue of the Drosophila headcase protein, HECA, is a novel tumor marker for early-stage colorectal cancer. Oncol Rep. 2006, 15: 919-926.PubMed
Metadata
Title
A predicted protein, KIAA0247, is a cell cycle modulator in colorectal cancer cells under 5-FU treatment
Authors
Chi-Jung Huang
Shung-Haur Yang
Shih-Ming Huang
Chih-Ming Lin
Chih-Cheng Chien
Yan-Chu Chen
Chia-Long Lee
Hao-Han Wu
Chun-Chao Chang
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2011
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-9-82

Other articles of this Issue 1/2011

Journal of Translational Medicine 1/2011 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.